ROBINUL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROBINUL (ROBINUL).
Antimuscarinic; competitively antagonizes acetylcholine at muscarinic receptors, inhibiting parasympathetic nerve impulses.
| Metabolism | Hepatic (minor); primarily excreted unchanged in urine. |
| Excretion | Biliary/fecal elimination is the primary route (approximately 80-85% of a dose is recovered in feces as unchanged drug and metabolites); renal excretion accounts for ~15-20% (mostly unchanged drug and active metabolite). |
| Half-life | Terminal elimination half-life is approximately 3–4 hours in healthy adults; in elderly or patients with renal impairment, half-life may be prolonged (up to 10 hours). Clinical context: Steady-state achieved within 24 hours; clinically insignificant accumulation with repeated dosing every 4–6 hours. |
| Protein binding | ~50% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 3–4 L/kg; indicates extensive tissue distribution (e.g., lung, liver, kidney) and poor CNS penetration due to quaternary ammonium structure. |
| Bioavailability | Oral: approximately 5–10% due to extensive first-pass metabolism; intramuscular: nearly 100%. |
| Onset of Action | Intravenous: 1–2 minutes; Intramuscular: 10–15 minutes; Oral: 30–60 minutes. |
| Duration of Action | Intravenous/Intramuscular: 4–6 hours; Oral: 3–4 hours. Note: Duration may be shorter in elderly or debilitated patients; antisialagogue effect may last up to 7 hours at higher doses. |
1-2 mg orally 3-4 times daily; 0.1-0.2 mg intramuscular or intravenous every 6-8 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended per manufacturer; use caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation. |
| Liver impairment | No specific guidelines; use with caution in Child-Pugh C cirrhosis due to reduced clearance. |
| Pediatric use | Oral: 0.01-0.02 mg/kg per dose, up to 0.2 mg/kg/day divided every 6-8 hours; rectal: 0.01-0.02 mg/kg per dose every 12 hours. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 0.5 mg orally 2-3 times daily) due to increased anticholinergic sensitivity and risk of cognitive impairment; titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROBINUL (ROBINUL).
| Breastfeeding | Excreted in breast milk in small amounts; M/P ratio unknown. Use with caution in nursing mothers due to potential anticholinergic effects in infant (e.g., decreased feeding, constipation, dry mouth). |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human studies. Avoid use in first trimester if possible; use only if clearly needed in second and third trimesters due to potential anticholinergic effects on fetus (e.g., tachycardia, meconium ileus). |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Myasthenia gravis (when not used for reversal of neuromuscular blockade)","Hypersensitivity to glycopyrrolate or any component","Narrow-angle glaucoma","Tachycardia","Obstructive uropathy"]
| Precautions | ["Use with caution in patients with coronary artery disease, congestive heart failure, arrhythmias, hypertension, hyperthyroidism, or prostatic hypertrophy.","May exacerbate glaucoma.","Monitor for anticholinergic effects (e.g., dry mouth, blurred vision, urinary retention)."] |
Loading safety data…
| Monitor maternal heart rate and blood pressure for anticholinergic effects; monitor fetal heart rate during labor if used parenterally due to risk of tachyarrhythmias. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Anticholinergic effects may reduce cervical mucus production, potentially affecting sperm transport; clinical significance unknown. |